<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="iso-abbrev">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="publisher-id">Neuropsychiatric Disease and Treatment</journal-id><journal-title-group><journal-title>Neuropsychiatric Disease and Treatment</journal-title></journal-title-group><issn pub-type="ppub">1176-6328</issn><issn pub-type="epub">1178-2021</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4208703</article-id><article-id pub-id-type="doi">10.2147/NDT.S71540</article-id><article-id pub-id-type="publisher-id">ndt-10-1997</article-id><article-categories><subj-group subj-group-type="heading"><subject>Corrigendum</subject></subj-group></article-categories><title-group><article-title>Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer&#x02019;s disease [Corrigendum]</article-title></title-group><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2014</year></pub-date><volume>10</volume><fpage>1997</fpage><lpage>1997</lpage><permissions><copyright-statement>&#x000a9; 2014 Hager et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d35e52" vol="10" page="391" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="24591834" ext-link-type="pubmed"/></article-meta></front><body><p>Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. <italic>Neuropsychiatr Dis Trea</italic>. 2014;10:391&#x02013;401.</p><p>On page 393, Figure 1, &#x0201c;Maintenance period (month 6 to 24)&#x0201d; should be &#x0201c;Maintenance period (month 4 to 24)&#x0201d;; &#x0201c;&#x02013; Gal at stable dose (at least 18 mg/day) as achieved on day 84<sup>c</sup>&#x0201d; should be &#x0201c;&#x02013; Gal at stable dose (at least 16 mg/day) as achieved on day 84<sup>c</sup>&#x0201d;. The correct figure is shown below.</p></body><floats-group><fig id="f1-ndt-10-1997" position="float"><caption><p><bold>Notes:</bold>
<sup>a</sup>Uptitration (from 16 mg/day to 24 mg/day) or downtitration (from 24 mg/day to 16 mg/day) of dose was allowed, based on tolerability and the investigator&#x02019;s judgment. Patients unable to tolerate a minimum of 16 mg/day dose were to discontinue treatment and were followed until the end of the maintenance and posttreatment period. The total number of patients included in the safety analysis set was n=2,045; <sup>b</sup>early study termination, per Data Safety Monitoring Board recommendation, when the prespecified number of deaths was ascertained and a significant imbalance favoring galantamine was observed; <sup>c</sup>a one-time dose titration to 16 or 24 mg/day was allowed, based on the investigator&#x02019;s judgment and patient tolerability.</p><p><bold>Abbreviation:</bold> Gal, galantamine.</p></caption><graphic xlink:href="ndt-10-1997Fig1"/></fig></floats-group></article>